Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss: meta-analysis of randomized controlled trials
Lippincott, Williams and Wilkins
MetadataDangos cofnod eitem llawn
Background and objective: Glucocorticoids are the standard treatment for idiopathic sudden sensorineural hearing loss (ISSNHL), but whether intratympanic or systemic therapy is superior remains controversial. Previous meta-analyses of this question have omitted key clinical trials or included observational studies. Methods: English-language randomized controlled trials in OVIDSP, PUBMED, EMBASE, CINAHL and the Cochrane Library comparing intratympanic vs. systemic glucocorticoid therapy for ISSNHL were meta-analyzed using RevMan 5.3. The primary outcome of interest was improvement in pure tone average (PTA) threshold. Results: Six trials involving 248 patients receiving intratympanic steroids and 236 receiving systemic steroids were meta-analyzed. PTA thresholds were similar between the two groups at 3 months after therapy initiation (mean difference, 0.24; 95%CI -2.43 to 2.91, P=.86; I2= 54%, P=.07, random-effects model). PTA thresholds were also similar at 6 months (mean difference, 4.69, 95%CI -5.84 to 15.22, P =.38), although the results showed extremely high heterogeneity (I2= 98%). Sensitivity analysis indicated that a single trial containing 250 patients provided the strongest evidence for equivalence between the two types of therapy. Rates of recovery within 3 months (defined as PTA improvement >10 dB) were similar between the two types of therapy(OR 0.92, 95%CI 0.59 to 1.43, P=.70), with no significant heterogeneity in the pooled data (I2=1%, P=.40). Conclusion: Intratympanic and systemic steroids therapies appear to show similar short-term efficacy for restoring hearing in patients with ISSNHL. Intratympanic therapy may reduce systemic side effects associated with steroid use.
Lai, D., Zhao, F., Jalal, N. and Zheng, Y. (2017) Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss: Meta-analysis of randomized controlled trials. Medicine, 96(50), p.e8955.
Dynodwr Gwrthrych Digidol (DOI)http://dx.doi.org/10.1097/MD.0000000000008955
This article was published in Medicine in December 2017 available open access at http://dx.doi.org/10.1097/MD.0000000000008955
Yn dangos eitemau sy’n perthyn drwy deitl, awdur, pwnc a chrynodeb.
Validity and Reliability of Surface Electromyography Measurements from a Wearable Athlete Performance System Lynn, Scott; Watkins, Casey; Wong, Megan; Balfany, Katherine; Feeney, Daniel (University of Uludag, 2018-05-14)The Athos ® wearable system integrates surface electromyography (sEMG ) electrodes into the construction of compression athletic apparel. The Athos system reduces the complexity and increases the portability of collecting ...
Supporting carers to manage pain medication in cancer patients at the end of life: A feasibility trial Latter, Sue; Hopkinson, Jane; Lowson, Elizabeth; Hughes, Jane; Hughes, Jacqueline; Duke, Sue; Anstey, Sally; Bennett, Michael; May, Carl; Smith, Peter; Richardson, Alison (Sage, 2017-07-05)Background: Carers of people with advanced cancer play a significant role in managing pain medication, yet they report insufficient information and support to do so confidently and competently. There is limited research ...
The evaluation of using high performance liquid chromatography as a method of monitoring vitamin D2 and D3 concentrations in patients Jones, Laura (Cardiff Metropolitan University, 2010)Vitamin D is actually a steroid hormone. It exists in two forms; Vitamin D2 and D3 and can be introduced into a person via dietary intake or by the conversion of cholesterol in the skin by UV radiation, which initiates a ...